Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK Cells with ASCT for B-Cell Lymphoma
NCT03579927Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR NK cells in B cell lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events and Complete response (CR) or partial response (PR). Planned start Oct 2019; status: withdrawn.
02
Drugs
CD19 CAR NK cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03579927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579927.